APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biologics and Biosimilars Market Analysis and Forecast 2026-2032

26 December 2025203 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Biologics and Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biologics and Biosimilars, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biologics and Biosimilars, also provides the revenue of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics and Biosimilars revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biologics and Biosimilars revenue, projected growth trends, production technology, application and end-user industry.

Biologics and Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Pfizer

AbbVie

United Laboratory

Tonghua Dongbao

Sobi

Novo Nordisk

Kanghong Pharma

Innovent Biologics

Gan&Lee

Eli Lilly

Changchun High Tech

Celltrion

Biogen

Amgen

3SBIO

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biologics and Biosimilars company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilars revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Monoclonal Antibodies Major Player Table 3. Interferon Major Player Table 4. Insulin Major Player Table 5. Vaccines Major Player Table 6. Others Major Player Table 7. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Retail Pharmacy Major Player Table 10. Other Major Player Table 11. Biologics and Biosimilars Industry Trends Table 12. Biologics and Biosimilars Industry Drivers Table 13. Biologics and Biosimilars Industry Opportunities and Challenges Table 14. Biologics and Biosimilars Industry Restraints Table 15. Global Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Biologics and Biosimilars Market Share by Region (2021-2026) Table 18. Global Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Biologics and Biosimilars Market Share by Region (2027-2032) Table 20. Global Biologics and Biosimilars Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Biologics and Biosimilars Revenue Market Share by Players (2021-2026) Table 22. Global Biologics and Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Biologics and Biosimilars Key Players Headquarters & Area Served Table 24. Global Biologics and Biosimilars Players, Product Type & Application Table 25. Global Biologics and Biosimilars Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Biologics and Biosimilars by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Biologics and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 32. Global Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 33. Global Biologics and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 37. Global Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi Biologics and Biosimilars Product Portfolio Table 42. Sanofi Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Novartis Biologics and Biosimilars Product Portfolio Table 52. Novartis Recent Development Table 53. Merck Company Information Table 54. Merck Business Overview Table 55. Merck Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Merck Biologics and Biosimilars Product Portfolio Table 57. Merck Recent Development Table 58. Roche Company Information Table 59. Roche Business Overview Table 60. Roche Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Roche Biologics and Biosimilars Product Portfolio Table 62. Roche Recent Development Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Pfizer Biologics and Biosimilars Product Portfolio Table 67. Pfizer Recent Development Table 68. AbbVie Company Information Table 69. AbbVie Business Overview Table 70. AbbVie Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. AbbVie Biologics and Biosimilars Product Portfolio Table 72. AbbVie Recent Development Table 73. United Laboratory Company Information Table 74. United Laboratory Business Overview Table 75. United Laboratory Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. United Laboratory Biologics and Biosimilars Product Portfolio Table 77. United Laboratory Recent Development Table 78. Tonghua Dongbao Company Information Table 79. Tonghua Dongbao Business Overview Table 80. Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Tonghua Dongbao Biologics and Biosimilars Product Portfolio Table 82. Tonghua Dongbao Recent Development Table 83. Sobi Company Information Table 84. Sobi Business Overview Table 85. Sobi Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Sobi Biologics and Biosimilars Product Portfolio Table 87. Sobi Recent Development Table 88. Novo Nordisk Company Information Table 89. Novo Nordisk Business Overview Table 90. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 92. Novo Nordisk Recent Development Table 93. Kanghong Pharma Company Information Table 94. Kanghong Pharma Business Overview Table 95. Kanghong Pharma Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Kanghong Pharma Biologics and Biosimilars Product Portfolio Table 97. Kanghong Pharma Recent Development Table 98. Innovent Biologics Company Information Table 99. Innovent Biologics Business Overview Table 100. Innovent Biologics Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Innovent Biologics Biologics and Biosimilars Product Portfolio Table 102. Innovent Biologics Recent Development Table 103. Gan&Lee Company Information Table 104. Gan&Lee Business Overview Table 105. Gan&Lee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Gan&Lee Biologics and Biosimilars Product Portfolio Table 107. Gan&Lee Recent Development Table 108. Eli Lilly Company Information Table 109. Eli Lilly Business Overview Table 110. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Eli Lilly Biologics and Biosimilars Product Portfolio Table 112. Eli Lilly Recent Development Table 113. Changchun High Tech Company Information Table 114. Changchun High Tech Business Overview Table 115. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 117. Changchun High Tech Recent Development Table 118. Celltrion Company Information Table 119. Celltrion Business Overview Table 120. Celltrion Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Celltrion Biologics and Biosimilars Product Portfolio Table 122. Celltrion Recent Development Table 123. Biogen Company Information Table 124. Biogen Business Overview Table 125. Biogen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Biogen Biologics and Biosimilars Product Portfolio Table 127. Biogen Recent Development Table 128. Amgen Company Information Table 129. Amgen Business Overview Table 130. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Amgen Biologics and Biosimilars Product Portfolio Table 132. Amgen Recent Development Table 133. 3SBIO Company Information Table 134. 3SBIO Business Overview Table 135. 3SBIO Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. 3SBIO Biologics and Biosimilars Product Portfolio Table 137. 3SBIO Recent Development Table 138. North America Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 139. North America Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 140. North America Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 144. North America Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 145. Europe Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 146. Europe Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 147. Europe Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 148. Europe Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 149. Europe Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Europe Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 151. Europe Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 152. China Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 153. China Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 154. China Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 155. China Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 156. Asia Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 159. Asia Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Biologics and Biosimilars Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Asia Biologics and Biosimilars Revenue by Region (US$ Million) & (2021-2026) Table 162. Asia Biologics and Biosimilars Revenue by Region (US$ Million) & (2027-2032) Table 163. SAMEA Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 164. SAMEA Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 165. SAMEA Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 166. SAMEA Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 167. SAMEA Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. SAMEA Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 169. SAMEA Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Image Figure 2. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Monoclonal Antibodies Image Figure 5. Interferon Image Figure 6. Insulin Image Figure 7. Vaccines Image Figure 8. Others Image Figure 9. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Retail Pharmacy Image Figure 13. Other Image Figure 14. Global Biologics and Biosimilars Market Size (US$ Million) & (2021-2032) Figure 15. Global Biologics and Biosimilars Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Biologics and Biosimilars Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Biologics and Biosimilars Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Biologics and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 22. Global Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Biologics and Biosimilars Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 25. North America Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 27. North America Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 28. North America Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 29. United States Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 34. Europe Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 35. Europe Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 36. Germany Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 46. China Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 47. Asia Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 49. Asia Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 50. Asia Biologics and Biosimilars Revenue Share by Region (2021-2032) Figure 51. Japan Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 59. SAMEA Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 60. SAMEA Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 61. Brazil Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • AbbVie
  • United Laboratory
  • Tonghua Dongbao
  • Sobi
  • Novo Nordisk
  • Kanghong Pharma
  • Innovent Biologics
  • Gan&Lee
  • Eli Lilly
  • Changchun High Tech
  • Celltrion
  • Biogen
  • Amgen
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biologics and Biosimilars Market by Type
  3. 1.2.1 Global Biologics and Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibodies
  5. 1.2.3 Interferon
  6. 1.2.4 Insulin
  7. 1.2.5 Vaccines
  8. 1.2.6 Others
  9. 1.3 Biologics and Biosimilars Market by Application
  10. 1.3.1 Global Biologics and Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Retail Pharmacy
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Biologics and Biosimilars Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biologics and Biosimilars Market Perspective (2021-2032)
  2. 3.2 Global Biologics and Biosimilars Growth Trends by Region
  3. 3.2.1 Global Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biologics and Biosimilars Market Size by Region (2021-2026)
  5. 3.2.3 Global Biologics and Biosimilars Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biologics and Biosimilars Revenue by Players
  2. 4.1.1 Global Biologics and Biosimilars Revenue by Players (2021-2026)
  3. 4.1.2 Global Biologics and Biosimilars Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biologics and Biosimilars Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biologics and Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biologics and Biosimilars Key Players Headquarters & Area Served
  7. 4.4 Global Biologics and Biosimilars Players, Product Type & Application
  8. 4.5 Global Biologics and Biosimilars Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biologics and Biosimilars Market CR5 and HHI
  11. 4.6.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
5 Biologics and Biosimilars Market Size by Type
  1. 5.1 Global Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 5.3 Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032)
6 Biologics and Biosimilars Market Size by Application
  1. 6.1 Global Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biologics and Biosimilars Revenue by Application (2021-2032)
  3. 6.3 Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Biologics and Biosimilars Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Biologics and Biosimilars Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Biologics and Biosimilars Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Biologics and Biosimilars Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Biologics and Biosimilars Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 United Laboratory
  44. 7.8.1 United Laboratory Company Information
  45. 7.8.2 United Laboratory Business Overview
  46. 7.8.3 United Laboratory Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 7.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
  48. 7.8.5 United Laboratory Recent Developments
  49. 7.9 Tonghua Dongbao
  50. 7.9.1 Tonghua Dongbao Company Information
  51. 7.9.2 Tonghua Dongbao Business Overview
  52. 7.9.3 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
  54. 7.9.5 Tonghua Dongbao Recent Developments
  55. 7.10 Sobi
  56. 7.10.1 Sobi Company Information
  57. 7.10.2 Sobi Business Overview
  58. 7.10.3 Sobi Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sobi Biologics and Biosimilars Product Portfolio
  60. 7.10.5 Sobi Recent Developments
  61. 7.11 Novo Nordisk
  62. 7.11.1 Novo Nordisk Company Information
  63. 7.11.2 Novo Nordisk Business Overview
  64. 7.11.3 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  66. 7.11.5 Novo Nordisk Recent Developments
  67. 7.12 Kanghong Pharma
  68. 7.12.1 Kanghong Pharma Company Information
  69. 7.12.2 Kanghong Pharma Business Overview
  70. 7.12.3 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
  72. 7.12.5 Kanghong Pharma Recent Developments
  73. 7.13 Innovent Biologics
  74. 7.13.1 Innovent Biologics Company Information
  75. 7.13.2 Innovent Biologics Business Overview
  76. 7.13.3 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
  78. 7.13.5 Innovent Biologics Recent Developments
  79. 7.14 Gan&Lee
  80. 7.14.1 Gan&Lee Company Information
  81. 7.14.2 Gan&Lee Business Overview
  82. 7.14.3 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
  84. 7.14.5 Gan&Lee Recent Developments
  85. 7.15 Eli Lilly
  86. 7.15.1 Eli Lilly Company Information
  87. 7.15.2 Eli Lilly Business Overview
  88. 7.15.3 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  90. 7.15.5 Eli Lilly Recent Developments
  91. 7.16 Changchun High Tech
  92. 7.16.1 Changchun High Tech Company Information
  93. 7.16.2 Changchun High Tech Business Overview
  94. 7.16.3 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  96. 7.16.5 Changchun High Tech Recent Developments
  97. 7.17 Celltrion
  98. 7.17.1 Celltrion Company Information
  99. 7.17.2 Celltrion Business Overview
  100. 7.17.3 Celltrion Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Celltrion Biologics and Biosimilars Product Portfolio
  102. 7.17.5 Celltrion Recent Developments
  103. 7.18 Biogen
  104. 7.18.1 Biogen Company Information
  105. 7.18.2 Biogen Business Overview
  106. 7.18.3 Biogen Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Biogen Biologics and Biosimilars Product Portfolio
  108. 7.18.5 Biogen Recent Developments
  109. 7.19 Amgen
  110. 7.19.1 Amgen Company Information
  111. 7.19.2 Amgen Business Overview
  112. 7.19.3 Amgen Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Amgen Biologics and Biosimilars Product Portfolio
  114. 7.19.5 Amgen Recent Developments
  115. 7.20 3SBIO
  116. 7.20.1 3SBIO Company Information
  117. 7.20.2 3SBIO Business Overview
  118. 7.20.3 3SBIO Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  119. 7.20.4 3SBIO Biologics and Biosimilars Product Portfolio
  120. 7.20.5 3SBIO Recent Developments
8 North America
  1. 8.1 North America Biologics and Biosimilars Revenue (2021-2032)
  2. 8.2 North America Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 8.2.1 North America Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 8.2.2 North America Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 8.3 North America Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 8.4 North America Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 8.4.1 North America Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 8.4.2 North America Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 8.5 North America Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 8.6 North America Biologics and Biosimilars Revenue by Country
  11. 8.6.1 North America Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 8.6.3 North America Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biologics and Biosimilars Revenue (2021-2032)
  2. 9.2 Europe Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 9.3 Europe Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 9.5 Europe Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biologics and Biosimilars Revenue by Country
  11. 9.6.1 Europe Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biologics and Biosimilars Revenue (2021-2032)
  2. 10.2 China Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 10.2.1 China Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 10.2.2 China Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 10.3 China Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 10.4 China Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 10.4.1 China Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 10.4.2 China Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 10.5 China Biologics and Biosimilars Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biologics and Biosimilars Revenue (2021-2032)
  2. 11.2 Asia Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 11.3 Asia Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 11.5 Asia Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biologics and Biosimilars Revenue by Country
  11. 11.6.1 Asia Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biologics and Biosimilars Revenue (2021-2032)
  2. 12.2 SAMEA Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biologics and Biosimilars Revenue by Country
  11. 12.6.1 SAMEA Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst